Allena Pharmaceuticals, Inc.
DelistedCIK 1624658fmd_09XKBVV5PMAEEF5MQCNRD5JSV2Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2015 to Jun 30, 2022, 27 periods
| Line item | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 |
|---|---|---|---|---|---|---|---|
| Research and development | 12 | 20 | 16 | 26 | 37 | 20 | 35 |
| Total operating expenses | – | 24 | 21 | 36 | 48 | 32 | 48 |
| Operating income | – | (24) | (21) | (36) | (48) | (32) | (48) |
| Other non-operating income (expense) | (0) | (0) | (1) | (0) | 0 | (1) | (1) |
| Income tax expense | – | – | 0 | 0 | 0 | 0 | 0 |
| Net income | (14) | (25) | (22) | (36) | (47) | (33) | (49) |
| Net income to common shareholders | (14) | (25) | (22) | (36) | (47) | (33) | (49) |